Current News

Contact | Print version | PDF version | Send article | RSS-Feed

AEterna Zentaris Announces Completion of Patient Enrollment for Ozarelix Phase II Trial in Benign Prostatic Hyperplasia

23 Nov 2005 - AEterna Zentaris Inc. announced it has completed enrollment of 144 patients for a Phase II trial with ozarelix (D-63153) in benign prostatic hyperplasia (BPH), more than four months ahead of schedule. The randomized, placebo-controlled multi-center clinical trial is designed to evaluate both objective parameters, such as improvement in urine flow and shrinkage of the prostate volume, as well as various symptoms of BPH over a period of several months. The trial is being conducted in Europe with the collaboration of Spectrum Pharmaceuticals Inc. and results are expected to be disclosed during the second half of 2006.